Home Healthcare Pharmaceuticals Cancer Vaccines Market

Cancer Vaccines Market Size, Share & Trends Analysis Report By Type (Preventive Vaccines, Therapeutic Vaccines), By Technology (Cell-based Vaccines, Recombinant Vaccines, Viral Vector & DNA Cancer Vaccines, Others), By Indication (Prostate Cancer, Bladder Cancer, Cervical Cancer, Others), By Region (North America, Europe, Asia Pacific, Middle East & Africa, Latin America) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: August 21, 2026 | Author: Debashree Bora | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Cancer Vaccines Market, By Type 2022-2034 (USD MILLION/ Units)
    1. Preventive Vaccines
    2. Therapeutic Vaccines
  2. Cancer Vaccines Market, By Technology 2022-2034 (USD MILLION/ Units)
    1. Cell-based Vaccines
    2. Recombinant Vaccines
    3. Viral Vector & DNA Cancer Vaccines
    4. Others
  3. Cancer Vaccines Market, By Indication 2022-2034 (USD MILLION/ Units)
    1. Prostate Cancer
    2. Bladder Cancer
    3. Cervical Cancer
    4. Others
  4. Regional Cancer Vaccines Market
    1. North America
      1. North America Cancer Vaccines Market By Type 2022-2034 (USD MILLION/ Units)
        1. Preventive Vaccines
        2. Therapeutic Vaccines
      2. North America Cancer Vaccines Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Cell-based Vaccines
        2. Recombinant Vaccines
        3. Viral Vector & DNA Cancer Vaccines
        4. Others
      3. North America Cancer Vaccines Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Bladder Cancer
        3. Cervical Cancer
        4. Others
      4. U.S.
        1. Preventive Vaccines
        2. Therapeutic Vaccines
        3. Cell-based Vaccines
        4. Recombinant Vaccines
        5. Viral Vector & DNA Cancer Vaccines
        6. Others
        7. Prostate Cancer
        8. Bladder Cancer
        9. Cervical Cancer
        10. Others
      5. Canada
        1. Preventive Vaccines
        2. Therapeutic Vaccines
        3. Cell-based Vaccines
        4. Recombinant Vaccines
        5. Viral Vector & DNA Cancer Vaccines
        6. Others
        7. Prostate Cancer
        8. Bladder Cancer
        9. Cervical Cancer
        10. Others
    2. Europe
      1. Europe Cancer Vaccines Market By Type 2022-2034 (USD MILLION/ Units)
        1. Preventive Vaccines
        2. Therapeutic Vaccines
      2. Europe Cancer Vaccines Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Cell-based Vaccines
        2. Recombinant Vaccines
        3. Viral Vector & DNA Cancer Vaccines
        4. Others
      3. Europe Cancer Vaccines Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Bladder Cancer
        3. Cervical Cancer
        4. Others
      4. U.K.
        1. Preventive Vaccines
        2. Therapeutic Vaccines
        3. Cell-based Vaccines
        4. Recombinant Vaccines
        5. Viral Vector & DNA Cancer Vaccines
        6. Others
        7. Prostate Cancer
        8. Bladder Cancer
        9. Cervical Cancer
        10. Others
      5. Germany
        1. Preventive Vaccines
        2. Therapeutic Vaccines
        3. Cell-based Vaccines
        4. Recombinant Vaccines
        5. Viral Vector & DNA Cancer Vaccines
        6. Others
        7. Prostate Cancer
        8. Bladder Cancer
        9. Cervical Cancer
        10. Others
      6. France
        1. Preventive Vaccines
        2. Therapeutic Vaccines
        3. Cell-based Vaccines
        4. Recombinant Vaccines
        5. Viral Vector & DNA Cancer Vaccines
        6. Others
        7. Prostate Cancer
        8. Bladder Cancer
        9. Cervical Cancer
        10. Others
      7. Spain
        1. Preventive Vaccines
        2. Therapeutic Vaccines
        3. Cell-based Vaccines
        4. Recombinant Vaccines
        5. Viral Vector & DNA Cancer Vaccines
        6. Others
        7. Prostate Cancer
        8. Bladder Cancer
        9. Cervical Cancer
        10. Others
      8. Italy
        1. Preventive Vaccines
        2. Therapeutic Vaccines
        3. Cell-based Vaccines
        4. Recombinant Vaccines
        5. Viral Vector & DNA Cancer Vaccines
        6. Others
        7. Prostate Cancer
        8. Bladder Cancer
        9. Cervical Cancer
        10. Others
      9. Russia
        1. Preventive Vaccines
        2. Therapeutic Vaccines
        3. Cell-based Vaccines
        4. Recombinant Vaccines
        5. Viral Vector & DNA Cancer Vaccines
        6. Others
        7. Prostate Cancer
        8. Bladder Cancer
        9. Cervical Cancer
        10. Others
      10. Nordic
        1. Preventive Vaccines
        2. Therapeutic Vaccines
        3. Cell-based Vaccines
        4. Recombinant Vaccines
        5. Viral Vector & DNA Cancer Vaccines
        6. Others
        7. Prostate Cancer
        8. Bladder Cancer
        9. Cervical Cancer
        10. Others
      11. Benelux
        1. Preventive Vaccines
        2. Therapeutic Vaccines
        3. Cell-based Vaccines
        4. Recombinant Vaccines
        5. Viral Vector & DNA Cancer Vaccines
        6. Others
        7. Prostate Cancer
        8. Bladder Cancer
        9. Cervical Cancer
        10. Others
      12. Rest of Europe
        1. Preventive Vaccines
        2. Therapeutic Vaccines
        3. Cell-based Vaccines
        4. Recombinant Vaccines
        5. Viral Vector & DNA Cancer Vaccines
        6. Others
        7. Prostate Cancer
        8. Bladder Cancer
        9. Cervical Cancer
        10. Others
    3. APAC
      1. APAC Cancer Vaccines Market By Type 2022-2034 (USD MILLION/ Units)
        1. Preventive Vaccines
        2. Therapeutic Vaccines
      2. APAC Cancer Vaccines Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Cell-based Vaccines
        2. Recombinant Vaccines
        3. Viral Vector & DNA Cancer Vaccines
        4. Others
      3. APAC Cancer Vaccines Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Bladder Cancer
        3. Cervical Cancer
        4. Others
      4. China
        1. Preventive Vaccines
        2. Therapeutic Vaccines
        3. Cell-based Vaccines
        4. Recombinant Vaccines
        5. Viral Vector & DNA Cancer Vaccines
        6. Others
        7. Prostate Cancer
        8. Bladder Cancer
        9. Cervical Cancer
        10. Others
      5. Korea
        1. Preventive Vaccines
        2. Therapeutic Vaccines
        3. Cell-based Vaccines
        4. Recombinant Vaccines
        5. Viral Vector & DNA Cancer Vaccines
        6. Others
        7. Prostate Cancer
        8. Bladder Cancer
        9. Cervical Cancer
        10. Others
      6. Japan
        1. Preventive Vaccines
        2. Therapeutic Vaccines
        3. Cell-based Vaccines
        4. Recombinant Vaccines
        5. Viral Vector & DNA Cancer Vaccines
        6. Others
        7. Prostate Cancer
        8. Bladder Cancer
        9. Cervical Cancer
        10. Others
      7. India
        1. Preventive Vaccines
        2. Therapeutic Vaccines
        3. Cell-based Vaccines
        4. Recombinant Vaccines
        5. Viral Vector & DNA Cancer Vaccines
        6. Others
        7. Prostate Cancer
        8. Bladder Cancer
        9. Cervical Cancer
        10. Others
      8. Australia
        1. Preventive Vaccines
        2. Therapeutic Vaccines
        3. Cell-based Vaccines
        4. Recombinant Vaccines
        5. Viral Vector & DNA Cancer Vaccines
        6. Others
        7. Prostate Cancer
        8. Bladder Cancer
        9. Cervical Cancer
        10. Others
      9. Taiwan
        1. Preventive Vaccines
        2. Therapeutic Vaccines
        3. Cell-based Vaccines
        4. Recombinant Vaccines
        5. Viral Vector & DNA Cancer Vaccines
        6. Others
        7. Prostate Cancer
        8. Bladder Cancer
        9. Cervical Cancer
        10. Others
      10. South East Asia
        1. Preventive Vaccines
        2. Therapeutic Vaccines
        3. Cell-based Vaccines
        4. Recombinant Vaccines
        5. Viral Vector & DNA Cancer Vaccines
        6. Others
        7. Prostate Cancer
        8. Bladder Cancer
        9. Cervical Cancer
        10. Others
      11. Rest of Asia-Pacific
        1. Preventive Vaccines
        2. Therapeutic Vaccines
        3. Cell-based Vaccines
        4. Recombinant Vaccines
        5. Viral Vector & DNA Cancer Vaccines
        6. Others
        7. Prostate Cancer
        8. Bladder Cancer
        9. Cervical Cancer
        10. Others
    4. Middle East and Africa
      1. Middle East and Africa Cancer Vaccines Market By Type 2022-2034 (USD MILLION/ Units)
        1. Preventive Vaccines
        2. Therapeutic Vaccines
      2. Middle East and Africa Cancer Vaccines Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Cell-based Vaccines
        2. Recombinant Vaccines
        3. Viral Vector & DNA Cancer Vaccines
        4. Others
      3. Middle East and Africa Cancer Vaccines Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Bladder Cancer
        3. Cervical Cancer
        4. Others
      4. UAE
        1. Preventive Vaccines
        2. Therapeutic Vaccines
        3. Cell-based Vaccines
        4. Recombinant Vaccines
        5. Viral Vector & DNA Cancer Vaccines
        6. Others
        7. Prostate Cancer
        8. Bladder Cancer
        9. Cervical Cancer
        10. Others
      5. Turkey
        1. Preventive Vaccines
        2. Therapeutic Vaccines
        3. Cell-based Vaccines
        4. Recombinant Vaccines
        5. Viral Vector & DNA Cancer Vaccines
        6. Others
        7. Prostate Cancer
        8. Bladder Cancer
        9. Cervical Cancer
        10. Others
      6. Saudi Arabia
        1. Preventive Vaccines
        2. Therapeutic Vaccines
        3. Cell-based Vaccines
        4. Recombinant Vaccines
        5. Viral Vector & DNA Cancer Vaccines
        6. Others
        7. Prostate Cancer
        8. Bladder Cancer
        9. Cervical Cancer
        10. Others
      7. South Africa
        1. Preventive Vaccines
        2. Therapeutic Vaccines
        3. Cell-based Vaccines
        4. Recombinant Vaccines
        5. Viral Vector & DNA Cancer Vaccines
        6. Others
        7. Prostate Cancer
        8. Bladder Cancer
        9. Cervical Cancer
        10. Others
      8. Egypt
        1. Preventive Vaccines
        2. Therapeutic Vaccines
        3. Cell-based Vaccines
        4. Recombinant Vaccines
        5. Viral Vector & DNA Cancer Vaccines
        6. Others
        7. Prostate Cancer
        8. Bladder Cancer
        9. Cervical Cancer
        10. Others
      9. Nigeria
        1. Preventive Vaccines
        2. Therapeutic Vaccines
        3. Cell-based Vaccines
        4. Recombinant Vaccines
        5. Viral Vector & DNA Cancer Vaccines
        6. Others
        7. Prostate Cancer
        8. Bladder Cancer
        9. Cervical Cancer
        10. Others
      10. Rest of MEA
        1. Preventive Vaccines
        2. Therapeutic Vaccines
        3. Cell-based Vaccines
        4. Recombinant Vaccines
        5. Viral Vector & DNA Cancer Vaccines
        6. Others
        7. Prostate Cancer
        8. Bladder Cancer
        9. Cervical Cancer
        10. Others
    5. LATAM
      1. LATAM Cancer Vaccines Market By Type 2022-2034 (USD MILLION/ Units)
        1. Preventive Vaccines
        2. Therapeutic Vaccines
      2. LATAM Cancer Vaccines Market By Technology 2022-2034 (USD MILLION/ Units)
        1. Cell-based Vaccines
        2. Recombinant Vaccines
        3. Viral Vector & DNA Cancer Vaccines
        4. Others
      3. LATAM Cancer Vaccines Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Bladder Cancer
        3. Cervical Cancer
        4. Others
      4. Brazil
        1. Preventive Vaccines
        2. Therapeutic Vaccines
        3. Cell-based Vaccines
        4. Recombinant Vaccines
        5. Viral Vector & DNA Cancer Vaccines
        6. Others
        7. Prostate Cancer
        8. Bladder Cancer
        9. Cervical Cancer
        10. Others
      5. Mexico
        1. Preventive Vaccines
        2. Therapeutic Vaccines
        3. Cell-based Vaccines
        4. Recombinant Vaccines
        5. Viral Vector & DNA Cancer Vaccines
        6. Others
        7. Prostate Cancer
        8. Bladder Cancer
        9. Cervical Cancer
        10. Others
      6. Argentina
        1. Preventive Vaccines
        2. Therapeutic Vaccines
        3. Cell-based Vaccines
        4. Recombinant Vaccines
        5. Viral Vector & DNA Cancer Vaccines
        6. Others
        7. Prostate Cancer
        8. Bladder Cancer
        9. Cervical Cancer
        10. Others
      7. Chile
        1. Preventive Vaccines
        2. Therapeutic Vaccines
        3. Cell-based Vaccines
        4. Recombinant Vaccines
        5. Viral Vector & DNA Cancer Vaccines
        6. Others
        7. Prostate Cancer
        8. Bladder Cancer
        9. Cervical Cancer
        10. Others
      8. Colombia
        1. Preventive Vaccines
        2. Therapeutic Vaccines
        3. Cell-based Vaccines
        4. Recombinant Vaccines
        5. Viral Vector & DNA Cancer Vaccines
        6. Others
        7. Prostate Cancer
        8. Bladder Cancer
        9. Cervical Cancer
        10. Others
      9. Rest of LATAM
        1. Preventive Vaccines
        2. Therapeutic Vaccines
        3. Cell-based Vaccines
        4. Recombinant Vaccines
        5. Viral Vector & DNA Cancer Vaccines
        6. Others
        7. Prostate Cancer
        8. Bladder Cancer
        9. Cervical Cancer
        10. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.